Oct 30, 2013 | Coding, Billing, and Collections, Compliance, Legal, and Malpractice, Instruments & Equipment, Laboratory Instruments & Laboratory Equipment, Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Extraneous tissue cross-contamination found in all participating pathology laboratories Cross-tissue contamination, regardless of specimen volume or how frequently reagents were changed
Pathologists and histotechnologists have long known that traditional methods of processing tissue for diagnosis have the potential to cross-contaminate human biopsy specimens. This risk to patient safety and diagnostic accuracy was accepted over the decades because of the limitations of technology and inability to more precisely measure the performance of individual work processes in the histology laboratory.
In recent years, two things have begun to change this long-standing status quo in medical laboratories. These developments now make it possible to more accurately measure the performance of histology work processes. In turn, this allows an understanding of the true rate of errors that happen from the time a human biopsy specimen arrives in the anatomic pathology laboratory until the completed slides are ready to be diagnosed by a pathologist. (more…)
Apr 9, 2012 | Compliance, Legal, and Malpractice, Laboratory Management and Operations, Laboratory News, Laboratory Operations, Laboratory Pathology, Management & Operations
Critics of an inquiry into histopathology errors at the Royal Bristol Infirmary argue that as many as 6,800 cases over eight year may have errors in diagnosis
In Bristol, England, the issue of serious errors in the anatomic pathology service of the Bristol Royal Infirmary (BRI) during the years 2000 to 2008 refuses to go away. Earlier this year, critics of an inquiry commissioned by the parent health trust became vocal once again after public notice was given of plans to consolidate histopathology services in the region.
These critics continue to be upset about how the inquiry into ongoing problems with the anatomic pathology service at BRI was conducted during 2009 and 2010. Newspapers in the United Kingdom have given the story wide play. Stories were published about pathology errors at BRI and the public learned about the misdiagnoses of specific cancer patients whose names became known.
(more…)
Oct 14, 2009 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Dark Daily Commentary: Treat lab testing as a commodity and risk disrupting the entire healthcare system
Once again, the pathology profession is seeing the consequences of the “penny wise-pound foolish” philosophy relentlessly pursued by government health bureaucrats. This time it involves the Auckland District Health Boards in New Zealand. Having signed a cut-rate, back room deal back in 2006 to save about NZ$15 million per year on lab testing (against an annual healthcare budget in the region of more than NZ$2.5 billion), these health officials are reaping a harvest of voluminous problems and deficiencies in the community because of problems with their new monopoly laboratory testing provider.
Many regular Dark Daily readers know that, ever since Labtests began its contract as the exclusive provider of pathology services and lab testing to the greater Auckland region late this summer, there has been chaos across the healthcare system. Labtests is a new business division of Healthscope Limited, (SYD:HSP) a public company based in Melbourne, Australia. See Dark Daily e-briefing “Long-Awaited Lab Contract Transition in New Zealand Happens Next Monday”.
(more…)
Jun 1, 2009 | Laboratory Management and Operations, Laboratory News, Laboratory Pathology
Health minister characterizes reports of 20% to 30% error rates as highly exaggerated
Questions about a possible high rate of errors in breast cancer testing done in the Canadian province of Quebec surfaced last week. Government health officials were forced to publicly acknowledge that they had received a report in April of a limited study that indicated an error rate of between 15% and 20% in hormone receptor testing, and an error rate as high as 30% in HER2/neu testing.
Following the first news reports of this situation last Thursday, Quebec health officials scrambled to respond to public concerns. In response to calls for the Health Ministry to release the full report to the public, Quebec’s Health Minister, Yves Bolduc, convened an extraordinary Sunday meeting that took place yesterday. He met with pathologists and oncologists from the province to review the details of the report on errors in breast cancer testing and determine a course of action.
(more…)
